J. Calabrese

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
J Calabrese, J.r. Calabrese, J. R. Calabrese, Joseph R Calabrese, J. R Calabrese, Joseph Calabrese, J R Calabrese, J. Calabrese, Joseph R. Calabrese, Joe Calabrese
Publication record
572 papers · 41,035 citations · H-index 100

PAPERS

Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study.
202538 citationsauthor #10
Divergent Directionality of Immune Cell-Specific Protein Expression between Bipolar Lithium Responders and Non-Responders Revealed by Enhanced Flow Cytometry
20239 citationsauthor #5
Focal adhesion is associated with lithium response in bipolar disorder: evidence from a network-based multi-omics analysis
202322 citationsauthor #14
Contributions of circadian clock genes to cell survival in fibroblast models of lithium-responsive bipolar disorder.
20239 citationsauthor #11
Differences in intracellular protein levels in monocytes and CD4+ lymphocytes between bipolar depressed patients and healthy controls: A pilot study with tyramine-based signal-amplified flow cytometry.
20235 citationsauthor #5
Cingulum bundle connectivity in treatment-refractory compared to treatment-responsive patients with bipolar disorder and healthy controls: a tractography and surgical targeting analysis.
20224 citationsauthor #5
The Relationship of Attention-Deficit/Hyperactivity Disorder With Posttraumatic Stress Disorder: A Two-Sample Mendelian Randomization and Population-Based Sibling Comparison Study.
202224 citationsauthor #48
Childhood trauma and treatment outcomes during mood‐stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder
202213 citationsauthor #8
Protein Biomarkers in Monocytes and CD4+ Lymphocytes for Predicting Lithium Treatment Response of Bipolar Disorder: a Feasibility Study with Tyramine-Based Signal-Amplified Flow Cytometry.
202216 citationsauthor #4
Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes
202211 citationsauthor #4
Treatments for Depression in Bipolar II Disorder.
20220 citationsauthor #3
Lumateperone (ITI-007) in the Treatment of Bipolar Depression: Results from a Randomized Clinical Trial.
20216 citationsauthor #8
The efficacy of cariprazine on function in patients with bipolar depression: a post hoc analysis of a randomized controlled trial
202120 citationsauthor #2
Correction to: Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)
20211 citationsauthor #13
Clinical predictors of non‐response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study
202127 citationsauthor #49
Cohort profile: the Ohio Army National Guard Mental Health Initiative (OHARNG-MHI)
20210 citationsauthor #5
A Machine Learning Approach to Predicting New‐onset Depression in a Military Population
202117 citationsauthor #6
Evaluation of MADRS severity thresholds in patients with bipolar depression.
202124 citationsauthor #3
Development of a Patient-Centered Software System to Facilitate Effective Management of Bipolar Disorder.
20219 citationsauthor #5
Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response.
20218 citationsauthor #5
Enhancing Discovery of Genetic Variants for Posttraumatic Stress Disorder Through Integration of Quantitative Phenotypes and Trauma Exposure Information
202142 citationsauthor #37
Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.
202181 citationsauthor #1
Cardiometabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response.
202112 citationsauthor #7
Correction of depression‐associated circadian rhythm abnormalities is associated with lithium response in bipolar disorder
202119 citationsauthor #45
Circadian rhythms in bipolar disorder patient-derived neurons predict lithium response: Preliminary studies
202138 citationsauthor #11
The mechanisms of action of lithium in bipolar disorder
20214 citationsauthor #2
The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study.
202017 citationsauthor #17
A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia
2020190 citationsauthor #11
Connectivity-based identification of a potential neurosurgical target for mood disorders.
20209 citationsauthor #6
Direct incremental healthcare costs associated with mood disorders in the United States, 2007-2017.
20208 citationsauthor #3
P.446 Efficacy and safety of lumateperone (ITI-007) in the treatment of depressive episodes associated with bipolar I and II disorders
20200 citationsauthor #9
The association between lithium use and neurocognitive performance in patients with bipolar disorder
202040 citationsauthor #10
Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials
20207 citationsauthor #6
Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder at Any Phase of Illness and at least Mild Symptom Severity.
20206 citationsauthor #10
Parent General Behavior Inventory
20200 citationsauthor #4
Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)
202079 citationsauthor #13
Psychological trauma and the genetic overlap between posttraumatic stress disorder and major depressive disorder
202021 citationsauthor #13
Major depressive disorder with mixed features and treatment response to lurasidone: A symptom network model.
202015 citationsauthor #6
Familial severe psychiatric history in bipolar disorder and correlation with disease severity and treatment response.
202013 citationsauthor #8
The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
201912 citationsauthor #2
Double-blind, placebo-controlled trial of pioglitazone for bipolar depression.
201937 citationsauthor #12
47 Sustained Functional Recovery and Symptom Remission After Maintenance Treatment with Aripiprazole Once-Monthly for Patients with Bipolar I Disorder
20191 citationsauthor #7
Efficacy and safety of cariprazine in bipolar I depression: A double‐blind, placebo‐controlled phase 3 study
201975 citationsauthor #7
Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale.
201917 citationsauthor #17
Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship.
201917 citationsauthor #11
Prevalence and covariates of problematic gambling among a US military cohort.
201912 citationsauthor #7
International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci
2019516 citationsauthor #42
Sustained functional recovery and symptomatic remission after maintenance treatment with aripiprazole once-monthly in patients with bipolar I disorder
20190 citationsauthor #6
Genomic influences on self-reported childhood maltreatment
201970 citationsauthor #23
Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials
20194 citationsauthor #4
Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors.
201943 citationsauthor #11
Bipolar depression: the clinical characteristics and unmet needs of a complex disorder
2019148 citationsauthor #2
Molecular genetic overlap between posttraumatic stress disorder and sleep phenotypes.
201923 citationsauthor #36
Correlation between depression/anxiety symptom severity and quality of life in patients with major depressive disorder or bipolar disorder.
201976 citationsauthor #4
116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective κ Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients
20190 citationsauthor #10
Longitudinally Measured Changes in Somnolence Severity With a Visual Analog Scale in a Randomized Lithium Versus Quetiapine-IR Study in Bipolar Disorder
20195 citationsauthor #10
P.013 Symptom stability in de novo and rollover patients with bipolar I disorder receiving aripiprazole once-monthly in a 52-week, open-label study
20190 citationsauthor #1
Clinical Evaluation of Cingulum Bundle Connectivity for Neurosurgical Hypothesis Development.
20194 citationsauthor #7
Developing and Validating a Definition of Impulsive/Reactive Aggression in Youth
201915 citationsauthor #7
Original Article A Randomized, Placebo-Controlled 12-Month Trial of Divalproex and Lithium in Treatment of Outpatients With Bipolar I Disorder
20191 citationsauthor #2
Examining the Relationship Between PTSD Symptomatology and Cigarette Smoking Among Ohio Army National Guard Soldiers
20199 citationsauthor #12
A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression.
201927 citationsauthor #7
Regular Articles Clozapine for Treatment-Refractory Mania
20190 citationsauthor #1
Entrainment of Circadian Rhythms to Temperature Reveals Amplitude Deficits in Fibroblasts from Patients with Bipolar Disorder and Possible Links to Calcium Channels
201914 citationsauthor #9
Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression
20183 citationsauthor #10
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder
20181,471 citationsauthor #25
Subthreshold PTSD and PTSD in a prospective‐longitudinal cohort of military personnel: Potential targets for preventive interventions
201835 citationsauthor #4
The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.
201815 citationsauthor #1
Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trial.
201828 citationsauthor #7
Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder
20187 citationsauthor #8
A Pilot Study of the Effectiveness of Lithium Versus Quetiapine Immediate Release Monotherapy in Patients With Bipolar Spectrum Disorders
201815 citationsauthor #10
3.10 Replication and Extension of an Empirical Definition of Impulsive Aggression in Children
20180 citationsauthor #6
Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder.
201824 citationsauthor #1
Corrigendum to "General distress is more important than PTSD's cognitions and mood alterations factor in accounting for PTSD and depression's comorbidity" [J. Affect. Disord. 211 (2017) 118-123].
20181 citationsauthor #11
Chronotype and cellular circadian rhythms predict the clinical response to lithium maintenance treatment in patients with bipolar disorder
2018100 citationsauthor #16
Largest genome-wide association study for PTSD identifies genetic risk loci in European and African ancestries and implicates novel biological pathways
201826 citationsauthor #39
Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
201818 citationsauthor #1
The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development
201856 citationsauthor #7
Corrigendum to bipolar mixed features - Results from the comparative effectiveness for bipolar disorder (Bipolar CHOICE) study [Journal of Affective Disorders 217 (2017) 183-189].
20180 citationsauthor #16
Depression severity and quality of life of qualified and unqualified patients with a mood disorder for a research study targeting anhedonia in a clinical sample.
201720 citationsauthor #4
Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study.
2017110 citationsauthor #1
Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: A phase 3, randomized controlled trial.
201727 citationsauthor #2
Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder.
201721 citationsauthor #9
The Pharmacogenomics of Bipolar Disorder Study: A Combined Analysis Of Ips Neuronal Expression And Gwas Data Identifies Cbarp And Card19 As Associated With Lithium Response
20172 citationsauthor #4
Clinical correlates of acute bipolar depressive episode with psychosis.
201719 citationsauthor #15
Nonsteroidal anti‐inflammatory drugs (NSAIDs) and paracetamol do not affect 6‐month mood‐stabilizing treatment outcome among 482 patients with bipolar disorder
201712 citationsauthor #4
Ruminative Style Questionnaire--Short Form; Revised
20170 citationsauthor #7
Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder
201717 citationsauthor #9
Diagnosing Mania in the Age of DSM-5.
20178 citationsauthor #1
Coincident alcohol dependence and depression increases risk of suicidal ideation among Army National Guard soldiers.
201715 citationsauthor #6
A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use
201714 citationsauthor #6
White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder
201730 citationsauthor #4
Poor quality of life and functioning in bipolar disorder
201790 citationsauthor #10
Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder?
201718 citationsauthor #4
General distress is more important than PTSD's cognition and mood alterations factor in accounting for PTSD and depression's comorbidity.
201750 citationsauthor #11
Recurrence and recovery in aripiprazole once-monthly maintenance treatment of bipolar I disorder: a blinded, placebo-controlled, randomised study
20170 citationsauthor #2
Bipolar mixed features - Results from the comparative effectiveness for bipolar disorder (Bipolar CHOICE) study.
201714 citationsauthor #16
Deployment and Alcohol Use in a Military Cohort: Use of Combined Methods to Account for Exposure-Related Covariates and Heterogeneous Response to Exposure
20177 citationsauthor #3
Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder.
201743 citationsauthor #1
Caregiver Brooding Scale
20170 citationsauthor #7

TIMELINE

1983 4 citations

1984 5 citations

1985 96 citations

1986 215 citations

1987 51 citations

1988 2 citations

1989 173 citations

1990 295 citations

1991 403 citations

1992 158 citations

1993 278 citations

1994 1,703 citations

1995 689 citations

1996 631 citations

1997 670 citations

1998 77 citations

1999 609 citations

2000 2,442 citations

2001 886 citations

2002 1,449 citations

2003 4,453 citations

2004 1,729 citations

2005 3,390 citations

2006 2,388 citations

2007 2,899 citations

2008 1,723 citations

2009 2,792 citations

2010 813 citations

2011 460 citations

2012 806 citations

2013 1,179 citations

2014 957 citations

2015 1,330 citations

2016 850 citations

2017 558 citations

2018 1,799 citations

2019 1,126 citations

2020 405 citations

2021 308 citations

2022 68 citations

2023 45 citations

2025 38 citations

Unknown 105 citations

J. Calabrese

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT